Market Overview

Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS Estimates For The Next Quarter

Share:
Related BIIB
Despite Drug Trial Miss, Here's Why Biogen Should Trade Higher
Technical Alert: Biogen Inc. Higher Off Trial Results For Aducanumab
Biogen Underplays Promising Alzheimer's Data On Seizure Worries (Investor's Business Daily)
Related AMGN
10 Stocks With Lowest Close In Three Weeks
Karyopharm Therapeutics' Top Execs Talk Recent Results In Multiple Myeloma And Acute Myeloid Leukemia
Will Trump Break With Republicans And Push Major Drug Price Reform? (Investor's Business Daily)

Below are the top biotechnology stocks on the NASDAQ in terms of earnings estimate for the next quarter.

Biogen Idec (NASDAQ: BIIB) is estimated to post earnings of $2.07 per share in the September quarter. Biogen Idec's trailing-twelve-month revenue is $5.64 billion.

Amgen (NASDAQ: AMGN) is expected to earn $1.80 per share in the September quarter. Amgen's trailing-twelve-month operating margin is 34.08%.

Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) is likely to earn $1.46 per share in the June quarter. Jazz Pharmaceuticals had $387.20 million in total cash for the latest quarter.

Celgene (NASDAQ: CELG) may earn $1.45 per share in the September quarter. Celgene's PEG ratio is 0.94.

Posted-In: Biotechnology Industry Highest EPS Estimates NASDAQ StocksTrading Ideas

 

Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!